This information is not intended for United States residents. Please click here if you reside in the United States.

ETHYOL® (amifostine)

What is it?

ETHYOL® contains the drug amifostine. Amifostine is in a class of medications called cytoprotectants which protect against the harmful effects of chemotherapy medications and radiation treatment.

ETHYOL® is licenced in many markets for the following uses:

  • Use in certain advanced ovarian carcinomas to reduce the neutropenia (low white blood cell count) related risk of infection (e.g. neutropenic fever) associated with cyclophosphamide and/or cisplatin;
  • Use in certain types of cancers (not including ovarian or testicular cancer) to reduce the risk of kidney damage which can be caused by cisplatin;
  • Use in cancer of the head and neck to reduce the risk of acute and late xerostomia (loss of saliva associated with an impression of a dry mouth), a side-effect caused by standard fractionated radiation therapy.

Marketing Authorisations

Please click on a country from the list below.  You will be directed to the regulatory agency website for the country you have selected, where you can find the registered prescribing information. The marketing authorisations are either held by Clinigen or their local partner.


More Information

Adverse Event Reporting Medical Enquiries